Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
at www.tipranks.com (Wed, 15-Apr 3:15 PM)
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
at www.tipranks.com (Mon, 13-Apr 10:36 AM)
PHVS Highlights Breakthrough Results for Deucrictibant in HAE Treatment: Phase 2 Data Show Promise for Both Prevention and Relief
Market Chameleon (Fri, 20-Mar 10:48 AM)
